B-cell Non-Hodgkin Lymphoma (B-NHL)Phase 2ELM-2NCT03888105
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
A Phase 2 study testing Odronextamab in people with B-cell Non-Hodgkin Lymphoma (B-NHL), run by Regeneron Pharmaceuticals at 119 sites in 14 countries.
Trial summary
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- What is being tested?
- Odronextamab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 515 participants
- Where
- 119 sitesin 14 countries
- Study dates
- 13 Nov 2019to 15 Dec 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- For the FL grade 1-3a cohort only: Central histopathologic confirmation of the FL Grade 1 to 3a diagnosis must be obtained before study enrollment. Patients with FL grade 3b are ineligible for this cohort but may be included in the "other B-NHL" cohort. Follicular lymphoma subtyping is based on the World Health Organization (WHO) classification (Swerdlow, 2017)
- Disease-specific cohorts:
- Patients should in the judgment of the investigator require systemic therapy for lymphoma at the time of study enrollment
- FL grade 1-3a cohort: Patients with FL grade 1-3a that has relapsed after or is refractory to at least 2 prior lines of systemic therapy, as defined in the protocol
- DLBCL cohort: Patients with DLBCL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol
- MCL after BTK inhibitor therapy cohort: Patients with MCL who have relapsed or refractory disease to at least one prior line of systemic therapy and had prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor
Show all 11Show fewer
- MZL cohort: Patients with MZL that have relapsed or is refractory to at least 2 prior lines of systemic therapy
- Other B-NHL cohort: Patients with B-NHL other than FL grade 1-3a, DLBCL, MCL, or MZL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol. New enrollment stopped for patients with Burkitt lymphoma and Burkitt-like lymphoma.
- Measurable disease on cross sectional imaging as defined in the protocol documented by diagnostic imaging (computed tomography (CT), or magnetic resonance imaging (MRI)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate bone marrow, hepatic, and renal function as defined in the protocol
Who cannot join
- Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS Non-Hodgkin Lymphoma (NHL) (suspected CNS lymphoma should be evaluated by lumbar puncture, as appropriate, in addition to the mandatory head CT or MRI)
- Treatment with any systemic anti-lymphoma therapy within 5 half-lives or within 28 days prior to first administration of study drug, whichever is shorter
- History of allogeneic stem cell transplantation, up to 12 months prior to first administration of study drug. The presence of acute or chronic graft-versus host disease (GVHD) will also be an exclusion
- Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent within 72 hours of start of study drug
- History of neurodegenerative condition or CNS movement disorder. Patients with a history of seizure within 12 months prior to study enrollment are excluded
- Another malignancy except B-NHL in the past 5 years, with the exception of non-melanoma skin cancer that has undergone potentially curative therapy or in situ cervical carcinoma, or any other tumor that has been deemed to be effectively treated with definitive local control and with curative intent
Show all 10Show fewer
- Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; cytomegalovirus (CMV) infection as noted by detectable levels on a blood polymerase chain reaction (PCR) assay as defined in the protocol or other uncontrolled infections
- Known hypersensitivity to both allopurinol and rasburicase
- Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy
- Note: Other protocol-defined Inclusion/Exclusion criteria apply
Trial locations and contacts
119 sites in 14 countries.
119 sites in 14 countries
China17 sites
Peking University Cancer Hospital (Beijing Cancer Hospital) (Beijing Institute for Cancer Research)
Beijing, Beijing Municipality, 100142
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730
Peking University - Third Hospital
Beijing, 100191
The First Bethune Hospital
Changchun, Jilin, 130021
West China Hospital
Chengdu, Sichuan, 610041
Second Affiliated Hospital - Xinqiao Hospital
Chongqing, Chongqing Municipality, 400000
Sun Yat-Sen University Cancer Center - Cancer Prevention and Treatment Center, Sun Yat-sen University
Guangzhou, Guangdong, 510000
The First Hospital affiliated to the Medical School of Zhejiang University
Hangzhou, Zhejiang, 310003
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009
The Affiliated Tumor Hospital
Harbin, Heilongjiang, 150081
Shanhai Cancer Center
Shanghai, Shanghai Municipality, 200032
The First Affiliated Hospital - Soochow University
Suzhou, Jiangsu, 215000
Institute of Hematology & Blood Diseases Hospital
Tianjin, Beijing Municipality, 300020
Tianjin Medical University Cancer Institute
Tianjin, Tianjin Municipality, 300060
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430030
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi, 710061
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000
Japan14 sites
Chiba Cancer Center
Chiba, Chiba, 260-8717
National Cancer Center Hospital - Tsukiji Campus
Chuo Ku, Tokyo, 104-0045
National Hospital Organization National Kyushu Cancer Center
Fukuoka, Hukuoka, 811-1395
Saitama Medical University International Medical Center
Hidaka, Saitama, 350-1298
Tokai University Hospital
Isehara-Shi, Kanagawa, 259-1193
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577
Kobe City Medical Center General Hospital
Kobe, Hyōgo, 650-0047
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, 602-8566
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, 791-0280
Japanese Red Cross Nagasaki Genbaku Hospital
Nagasaki, 852-8511
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
Nagoya, Aichi-ken, 466-8650
National Hospital Organization Nagoya Medical Center
Nagoya, Aiti, 460-0001
Osaka Metropolitan University Hospital
Osaka, Osaka, 545-8586
Yamagata University Hospital
Yamagata, Yamagata, 990-9585
United States13 sites
Tufts Medical Center
Boston, Massachusetts, 02111
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Rush University Medical Center
Chicago, Illinois, 60612
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, 75390
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey, 07601
University of Iowa
Iowa City, Iowa, 52242
Norton Cancer Institute
Louisville, Kentucky, 40207
Weill Cornell Medical College New York Presbyterian Hospital
New York, New York, 10021
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104
Mayo Clinic - Rochester
Rochester, Minnesota, 55905
Stony Brook University Hospital
Stony Brook, New York, 11794
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27257
Spain12 sites
Ico Lhospitalet - Hospital Duran i Reynals
Barcelona, Catalonia, 8907
Hospital Universitario Vall d'Hebron
Barcelona, 08035
Hospital Clinic de Barcelona - Planta 4 Escalera
Barcelona, 8036
Hospital de la Santa Creu i Sant Pau
Barcelona, 8041
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040
Hospital Universitario 12 de Octubre
Madrid, 28041
Hospital Universitario HM Sanchinarro
Madrid, 28050
Hospital Universitari Son Espases
Palma, Balearic Islands, 07120
Hospital Son Llatzer
Palma, Balearic Islands, 07198
Hospital Universitario Quiron Salud Madrid
Pozuelo de Alarcón, Madrid, 28223
Hospital Universitario de Salamanca
Salamanca, 37007
Hospital Universitari i Politecnic La Fe
Valencia, 46026
Italy10 sites
University of Bologna Dipartimento di Medicina Specialistica Diagnostica e Sperimentale
Bologna, 40138
Uos Ematologia - Ospedale Civile di Livorno
Livorno, 57124
UOC Hematologia, Fondazione IRCCS, Ca Granda, OM Policlinico
Milan, Milan, 20122
ASST Grande Ospedale Metropolitano Niguarda - Division of Hematology
Milan, 20162
AOU Maggiore della Carita
Novara, 28100
Presidio Ospedaliero Santa Maria della Misericordia
Perugia, 6156
Ospedale Santa Maria delle Croci
Ravenna, 48121
Arcispedale Santa Maria Nuova
Reggio Emilia, 42123
Ospedale dell'Angelo - Varese
Varese, 21100
Ospedale DellAngelo Di Mestre
Venice, 30174
France9 sites
Centre Hospitalier Universitaire de Caen - Hematologie Clinique IHBN
Caen, Calvados, 14000
Unite Hemopathies Lymphoides Hospital Henri Mondor
Créteil, Île-de-France Region, 94010
Hopital Claude Huriez - CHR Lille
Lille, Nord, 59037
CHU Hotel Dieu Service Hematologie
Nantes, Pays de la Loire Region, 44093
Hopital Saint Louis
Paris, 75010
Hospital de la Pitie-Salpetriere
Paris, 75651
Hopital Haut-Leveque
Pessac, Aquitaine, 33604
Hopital Lyon Sud
Pierre-Bénite, Lyon, 69310
Chu Poitiers - Pole Regional De Cancerologie
Poitiers, Vienne, 86000
Poland8 sites
Uniwersyteckie Centrum
Gdansk, Pomeranian Voivodeship, 80-214
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214
Pomorskie Hospitals SP. Z O. O. Oncology And Radiotherapy Ward
Gdynia, Pomeranian Voivodeship, 81519
Szpitale Pomorskie spSp. Z.o.o.
Gdynia, 81-519
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
Lodz, 93-513
Centrum Onkologii Instytut im M Sklodowskiej CurieOddzial Chorob United Kingdomladu Chlonnego
Warsaw, Masovian Voivodeship, 02-781
Instytut Hematologii I Transfuzjologii Klinika Hematologii
Warsaw, 02-776
Uniwersytecki Szpital Kliniczny we Wroclawiu, Klinika Hematologii, Terapii Komorkowych i Chorob Wewnetrznych
Wroclaw, 50-367
South Korea8 sites
Dong-A University Hospital
Busan, 49201
National Cancer Center
Gyeonggi-do, Gyeonggi-do, 10408
Seoul National University Hospital
Seoul, 3080
Severance Hospital
Seoul, 3722
Samsung Medical Center
Seoul, 6351
The Catholic University of Korea Seoul St Marys Hospital
Seoul, 6591
Ewha Womans University Mokdong Hospital - Hemato Oncology
Seoul, 7985
University of Ulsan College of Medicine
Ulsan, Daegu, 682-714
Taiwan8 sites
Chang Gung Memorial Hospital Kaohsiung
Kaohsiung City, 83301
China Medical University
Taichung, 40447
National Cheng Kung University
Tainan, 704
Chi-Mei Medical Center - Liuying
Tainan, 736
National Taiwan University Hospital
Taipei, 10002
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, 11251
Tri-Service General Hospital
Taipei, 11490
Chang Gung Medical Foundation-
Taoyuan, 333
Australia7 sites
Border Medical Oncology
East Albury, New South Wales, 2640
Epworth Hospital
East Melbourne, Victoria, VIC 3002
North Building
Frankston, Victoria, 3199
Andrew Love Cancer Centre
Geelong, Victoria, 3220
Olivia Newton John Cancer Wellness & Research Centre
Heidelberg, Victoria, VIC 3084
Royal Perth Hospital
Perth, Western Australia, 6000
Northern NSW Local Health District The Tweed Hospital
Tweed Heads, South Wales, 2485
United Kingdom5 sites
University Hospital of Wales
Cardiff, Wales, CF14 4XW
Kings College Hospital
London, SE5 9RS
Derriford Hospital and the Royal Eye Infirmary
Plymouth, Devon, PL6 8DH
The Royal Marsden Hospital
Sutton, Surrey, SM2 5PT
Royal Cornwall Hospital
Truro, Cornwall, TR1 3LJ
Germany3 sites
University Hospital Halle Saale
Halle, 6120
Kliniken Ostalb Stauferklinikum Schwab Gmund
Mutlangen, Gmund, D-73557
Universitatsklinik Wurzburg, Med Klinik und Poliklinik II, Zentrum Innere Medizin
Würzburg, 97080
Singapore3 sites
National University Hospital
Singapore, 119074
Singapore General Hospital
Singapore, 169608
Icon Soc Farrer Park
Singapore, 217562
Canada2 sites
Cross Cancer Institute
Edmonton, Alberta, T6G172
QEII Health Science Centre - Halifax location
Halifax, Nova Scotia, B3H 2Y9
About this study
Official title: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).
The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab.
The study is looking at several other research questions, including:
- To see if odronextamab works to destroy cancer cells
- Side effects that may be experienced by people taking odronextamab
- How odronextamab works in the body
- How much odronextamab is present in the blood
- Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Being tested
- Odronextamab
- Keywords
- Relapsed B-NHL, Refractory B-NHL, NHL, Follicular lymphoma (FL), Diffuse large B-cell lymphoma (DLBCL), Mantle cell lymphoma (MCL), Marginal zone lymphoma (MZL), bispecific antibody, CD20
- Medical subject headings
- Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, B-Cell, Marginal Zone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OdronextamabDrug
Also called REGN1979
Administered by intravenous (IV) infusion
| Study group | Role | What they receive |
|---|---|---|
| FL | Experimental | Follicular lymphoma grade 1-3a cohort Receives: Drug: Odronextamab |
| DLBCL | Experimental | Diffuse large B-cell lymphoma cohort Receives: Drug: Odronextamab |
| MCL | Experimental | Mantle Cell Lymphoma cohort Receives: Drug: Odronextamab |
| MZL | Experimental | Marginal Zone Lymphoma cohort Receives: Drug: Odronextamab |
| Other B-NHL | Experimental | Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia [WM]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed Receives: Drug: Odronextamab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate (ORR), as assessed by independent central review
FL grade 1-3a/MZL
Measured: Up to 52 weeks of study treatment
ORR, as assessed by independent central review
DLBCL/MCL/Other B-NHL
Measured: Up to 36 weeks of study treatment
Secondary outcomes (23)
ORR, as assessed by the local investigator
FL/MZL
Measured: Up to 52 weeks of study treatment
ORR, as assessed by the local investigator
DLBCL/MCL/Other B-NHL
Measured: Up to 36 weeks of study treatment
Complete Response (CR) Rate, as assessed by the local investigator
FL grade 1-3a/MZL
Measured: Up to 52 weeks of study treatment
CR rate, as assessed by independent central review
FL grade 1-3a/MZL
Measured: Up to 52 weeks of study treatment
CR rate, as assessed by the local investigator
DLBCL/MCL/Other B-NHL
Measured: Up to 36 weeks of study treatment
CR rate, as assessed by independent central review
DLBCL/MCL/Other B-NHL
Measured: Up to 36 weeks of study treatment
Progression-Free Survival (PFS), as assessed by independent central review
Measured: Approximately 194 weeks following the first dose
PFS, as assessed by the local investigator
Measured: Approximately 194 weeks following the first dose
Overall Survival (OS)
Measured: Approximately 194 weeks following the first dose
Duration Of Response (DOR), as assessed by independent central review
Measured: Approximately 194 weeks following the first dose
DOR, as assessed by the local investigator
Measured: Approximately 194 weeks following the first dose
Disease Control Rate (DCR), as assessed by independent central review
FL grade 1-3a/MZL
Measured: Up to 52 weeks of study treatment
DCR, as assessed by the local investigator
FL grade 1-3a/MZL
Measured: Up to 52 weeks of study treatment
DCR, as assessed by independent central review
DLBCL/MCL/Other B-NHL
Measured: Up to 36 weeks of study treatment
DCR, as assessed by the local investigator
DLBCL/MCL/Other B-NHL
Measured: Up to 36 weeks of study treatment
Incidence and severity of Treatment Emergent Adverse Events (TEAEs)
Measured: Approximately 194 weeks following the first dose
Concentration of odronextamab
End of infusion [EOI]; Concentration at a specified time t [Ct])
Measured: 12 weeks following end of treatment
Incidence of Anti-Drug Antibodies (ADA) to odronextamab over time
Measured: 12 weeks following end of treatment
Titer of anti-drug antibodies to odronextamab over time
Measured: 12 weeks following end of treatment
Incidence of Neutralizing antibodies (Nab) to odronextamab over time
Measured: 12 weeks following end of treatment
Changes in scores of patient-reported outcomes as measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)
The EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).
Measured: Approximately 194 weeks following the first dose
Changes in scores of patient-reported outcomes as measured by Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym)
Composed of the FACT-G plus the 15-item Lymphoma Subscale (LymS).
Measured: Approximately 194 weeks following the first dose
Changes in scores of patient-reported outcomes as measured by EuroQol-5 Dimensions-3 Levels (EQ-5D-3L)
The EQ-5D-3L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.
Measured: Approximately 194 weeks following the first dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2019
- Study start13 Nov 2019
- Primary completion17 Jun 2026
- Study completion15 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for B-cell Non-Hodgkin Lymphoma (B-NHL)Studies of the same condition, open and under way.
- More trials run by Regeneron PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- 5 cohorts The first 68 patients in the DLBCL cohort will be randomized; the remaining patients will not be randomized
- Masking
- None (open label)
- Enrolment
- 515 participants (actual)
Sponsor and investigators
- Lead sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trial Management, Study director, Regeneron Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03888105
- Sponsor's protocol ID
- R1979-ONC-1625
- Other IDs
- 2017-002139-41, 2024-511747-25-00, 2017
- Acronym
- ELM-2
- Status last verified
- Jul 2026
- First submitted
- 14 Mar 2019
- Last updated
- 31 Jul 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Publications
Villasboas JC, Poon M, Tani M, Jimenez-Ubieto A, Tessoulin B, Warwick L, Brown D, Namuduri M, Lin C, Delwart V, Jagadeesh D. Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study. Future Oncol. 2026 Mar;22(6):643-658. doi: 10.1080/14796694.2026.2628111. Epub 2026 Mar 1.
PubMed 41766170Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J. Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Adv. 2025 Dec 9;9(23):6130-6140. doi: 10.1182/bloodadvances.2025016332.
PubMed 40902079Danilov AV, Kambhampati Thiruvengadam S, Linton K, Cumings K, Chirikov V, Mutebi A, Bains Chawla S, Chhibber A, Rivas Navarro F, Marques Goncalves F, Wang A, Ding Z, Alshreef A, Favaro E, Hoehn D, Sureda A. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274.
PubMed 40472301Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jazdzewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17.
PubMed 40097657